Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P83105

UPID:
HTRA4_HUMAN

ALTERNATIVE NAMES:
High-temperature requirement factor A4

ALTERNATIVE UPACC:
P83105; Q542Z4; Q6PF13

BACKGROUND:
The Serine protease HTRA4, known alternatively as High-temperature requirement factor A4, is distinguished by its serine protease function. It is integral to the proteolytic degradation of denatured proteins, playing a pivotal role in cellular regulation and signaling. The enzyme's activity is essential for the proper execution of numerous cellular mechanisms, underlining its significance in biological systems.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of Serine protease HTRA4 presents a promising avenue for the development of novel therapeutic approaches. Given its critical role in maintaining cellular homeostasis, targeting HTRA4 could offer innovative solutions for conditions associated with its dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.